BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Vaccines

Hong Kong Pharma Stocks Surge as AIM Vaccine Secures U.S. Clinical Approval for mRNA RSV Vaccine

The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively into the pharmaceutical...

February 27, 2025 | News

Biological E. Partners with Bavarian Nordic to Manufacture Chikungunya Vaccine for LMICs in Asia, Africa, and Latin America

The manufacturing agreement is the first step in working together to provide Chikungunya Vaccine to low-and middle-income countries The initial t...

February 25, 2025 | News

SK Bioscience Advances mRNA Vaccine for Japanese Encephalitis with Phase 1/2 Trials in Australia and New Zealand

SK bioscience’s first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026. ...

February 25, 2025 | News

AIM Vaccine Accelerates Global Expansion with FDA Submissions for mRNA Shingles and RSV Vaccines

As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in China is in full swi...

February 25, 2025 | News

CanSinoBIO Showcases Vaccine Innovation and Global Health Commitment at 2025 World Government Summit

CanSino Biologics Inc. (CanSinoBIO or the Company), a leading Chinese vaccine innovator, has been invited to the 2025 World Government Summit in Dubai...

February 18, 2025 | News

AIM Vaccine Leads China's mRNA Innovation, Submits Breakthrough Shingles Vaccine for Clinical Trials

AIM Vaccine Co, a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA s...

February 12, 2025 | News

Merck’s CAPVAXIVE Recommended for EU Approval to Prevent Pneumococcal Disease in Adults

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...

February 03, 2025 | News

MSD’s GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the National Medical Products Administration (NMPA) of China ...

January 10, 2025 | News

DX&VX Advances Universal Coronavirus Vaccine to Address Breakthrough Infections and Variants

The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies. The accelerated approval and rapid distribution of&...

January 09, 2025 | News

DIOSynVax Introduces New Influenza Vaccine Portfolio and Advisory Board to Tackle Global Pandemic Threats

DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated ...

January 09, 2025 | News

WuXi Biologics to Sell $500M Irish Vaccine Facility to Merck & Co. Amid U.S. Legislative Pressures

WuXi Biologics has announced plans to sell its vaccine manufacturing facility in Dundalk, Ireland, to Merck & Co. for approximately $500 million. This ...

January 06, 2025 | News

Sanofi and SK Bioscience Forge Expanded Alliance to Combat Pneumococcal Disease with Next-Gen Vaccines

Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine ...

December 23, 2024 | News

SK bioscience to Launch Phase 1/2 Trials for First mRNA Vaccine Candidate in Australia

SK bioscience’s first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2...

December 13, 2024 | News

Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria

The Southern Hemisphere’s only mRNA manufacturing facility has officially opened in Victoria, marking a significant milestone for Australia’s h...

December 11, 2024 | News

Stay Connected